Try our beta test site
5 studies found for:    PF-04691502
Show Display Options
Rank Status Study
1 Completed
Has Results
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients
Condition: Cancer
Intervention: Drug: PF-04691502
2 Withdrawn Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: PF-04691502;   Drug: Exemestane
3 Terminated
Has Results
Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer
Conditions: Early Breast Cancer (Phase 2);   Advanced Breast Cancer (Phase 1b)
Interventions: Drug: PF-04691502;   Drug: PF-04691502 in combination with Letrozole;   Drug: Letrozole
4 Terminated
Has Results
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Condition: Endometrial Neoplasms
Intervention: Drug: PF-05212384
5 Terminated Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
Condition: Advanced Cancer
Interventions: Drug: PF-05212384;   Drug: PD-0325901;   Drug: irinotecan

Study has passed its completion date and status has not been verified in more than two years.